Redeye reviews the Integrum case and provides a more clear-cut take on its longer-term outlooks. In short, we only include above-knee in our sales forecasts and lengthen our forecast period to provide a more realistic view of its sales growth runway. Despite a strong share price momentum in the past 12 months, we highlight the discrepancy to relevant peers’ EV/sales multiples and see ample upside to our update DCF base case.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/